Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.
With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.
Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.
Top news of the day from across the health care landscape.
Tivozanib (Fotivda) improved progression-free survival and reduced risk of death in patients with highly refractory advanced or metastatic disease.
Hispanic adults in the US who are infected with human immunodeficiency virus face a greater risk of cancers caused by human papillomavirus (HPV) than Hispanics in the general public.
Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.